Literature DB >> 7053298

Heparin kinetics determined by three assay methods.

T D Bjornsson, K M Wolfram, B B Kitchell.   

Abstract

Heparin kinetics were determined in four normal subjects, each of whom received three different doses (25, 50, and 75 units/kg body weight) by intravenous injection. Multiple blood samples were collected after each dose and each plasma sample was assayed for heparin activity using three different assay methods. Two of these assays are based on coagulation tests, i.e., activated partial thromboplastin time and thrombin time, while the third is based on chemical neutralization of heparin using hexadimethrine bromide. Heparin kinetics showed pronounced dose-dependent changes, irrespective of the assay method used, which were characterized by increasing biologic half-life and decreasing total clearance (Cl) with increasing dose. No changes were noted in apparent volume of distribution (Vd). This data also showed that there were differences in kinetic parameters of heparin depending on the assay method. In general, values for total Cl and apparent Vd based on chemical neutralization were approximately 1.5 to 2.0 times these parameters based on coagulation tests. We conclude that the immediate mechanism of the dose-dependent heparin kinetics is decreasing total clearance with increasing dose and suggest that in vivo activation of the anticoagulant properties of heparin may explain the assay-dependent kinetics.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7053298     DOI: 10.1038/clpt.1982.16

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

Review 1.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

Review 2.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations.

Authors:  M Dryjski; D E Schneider; P Mojaverian; B S Kuo; T D Bjornsson
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

Review 4.  Revisiting the Pharmacology of Unfractionated Heparin.

Authors:  Abdallah Derbalah; Stephen Duffull; Fiona Newall; Katie Moynihan; Hesham Al-Sallami
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

Review 5.  Intravenous heparin dosing: patterns and variations in internists' practices.

Authors:  B M Reilly; R Raschke; S Srinivas; T Nieman
Journal:  J Gen Intern Med       Date:  1993-10       Impact factor: 5.128

6.  Assay-dependent kinetics of heparin: evidence for rapid in vivo activation of heparin.

Authors:  F X McGowan; P V Nash; T D Bjornsson
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

7.  Development and Implementation of a Standardized Heparin Protocol for Left-Sided Pediatric Electrophysiology Procedures.

Authors:  Emily F Moore; Jennifer Pak; Christa Jefferis-Kirk; Arlene Armatage; Richard A Kronmal; Jack C Salerno; Matthew D Files
Journal:  Pediatr Cardiol       Date:  2018-03-02       Impact factor: 1.655

Review 8.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

9.  Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients.

Authors:  Hesham Al-Sallami; Fiona Newall; Paul Monagle; Vera Ignjatovic; Noel Cranswick; Stephen Duffull
Journal:  Br J Clin Pharmacol       Date:  2016-05-02       Impact factor: 4.335

Review 10.  Heparin therapy. Regimens and treatment considerations.

Authors:  T M Hyers
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.